This addresses one of the limitations of PD-1/PD-L1 ICIs—that their effects are dependent on the tumor being immunologically ‘hot,’ containing an adequate number of TILs such as tumor-reactive T cells that can be de-repressed in the TME. This evidence concerns the gene CD274 and neoplasm.